제2형 당뇨병 환자에서 시타글립틴과 메트포민 고정 복합제 투여와 단일제 병용간의 복약 순응도, 효과 및 약가에 대한 비교 연구
Comparisons of Adherence, Efficacy and Price between Sitagliptin/Metformin Fixed-dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Type 2 Diabetes Mellitus Patients
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combinationtablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2diabetes mellitus. Methods: Adherence was measured as the medication possession ratio (MPR) of ≥80%, and MPRwas calculated as the number of total prescription days divided by the total treatment period. Hemoglobin A1C (HbA1c)differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved HbA1c lessthan 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metforminand sitagliptin/metformin tablets were investigated. Results: More than 90% of patients showed adherence inboth groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was nostatistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutivetimes tended to be somewhat higher in fixed dose combination group than in concomitant administration groupwithout a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin wascheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration. Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was notsignificantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixeddosecombination tablets were cheaper than concomitant administration of each tablet.
Abstract
Objective: This study was conducted to compare the adherence, clinical and economical utility of fixed-dose combinationtablets of sitagliptin/metformin with concomitant administration of sitagliptin and metformin in patients with type 2diabetes mellitus. Methods: Adherence was measured as the medication possession ratio (MPR) of ≥80%, and MPRwas calculated as the number of total prescription days divided by the total treatment period. Hemoglobin A1C (HbA1c)differences between baseline and predetermined periods were analyzed. Proportions of patients who achieved HbA1c lessthan 6.5% for three or more consecutive times were compared. To evaluate cost-effectiveness, prices of sitagliptin, metforminand sitagliptin/metformin tablets were investigated. Results: More than 90% of patients showed adherence inboth groups (92.0% in fixed-dose combination group vs 95.9% in concomitant administration group), and there was nostatistically significant difference (P = 0.113). Proportion of patients with HbA1c less than 6.5% for three or more consecutivetimes tended to be somewhat higher in fixed dose combination group than in concomitant administration groupwithout a statistically significant difference (32.6% vs. 28.0%, P = 0.344). Total price of metformin and sitagliptin wascheaper up to 222 KRW in the case of fixed-dose combination tablets compared to the case of concomitant administration. Conclusion: The sitagliptin/metformin fixed-dose combination tablet had a similar patient adherence and was notsignificantly different in efficacy to the concomitant administration of each component. In terms of drug prices, fixeddosecombination tablets were cheaper than concomitant administration of each tablet.
참고문헌 (20)
- Schellenberg ES., "Lifestyle Interventions for Patients With and at Risk for Type 2 DiabetesA Systematic Review and Meta-analysis", Ann Intern Med, 159(8), pp.543~551 (2013)
- Tuomilehto J., "Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance", N Engl J Med, 344(18), pp.1343~1350 (2001)
- Holman RR., "10-year follow-up of intensive glucose control in type 2 diabetes", N Engl J Med, 359(15), pp.1577~1589 (2008)
- Wild S., "Global prevalence of diabetes estimates for the year 2000 and projections for 2030", Diabetes Care, 27(5), pp.1047~1053 (2004)
- Ramachandran A., "Diabetes in Asia", Lancet, 375(9712), pp.408~418 (2010)
- American Diabetes Association., "American Diabetes Association (ADA) guidelines: clinical practice recommendations", Diabetes Care, 29(Suppl. 1), pp.S1~S85 (2006)
- 오지영, "당뇨병 진료지침 -대한당뇨병학회, 미국당뇨병학회, 유럽당뇨병학회, 일본당뇨병학회 권고안-", 대한내과학회지, 75(3), pp.249~256 (2008), 대한내과학회
- Inzucchi SE., "Management of hyperglycemia in type 2 diabetes : a patient-centered approach position statement of the American Diabetes Association(ADA)and the European Association for the Study of Diabetes(EASD)", Diabetes Care, 35(6), pp.1364~1379 (2012)
- Saenz A., "Metformin monotherapy for type 2 diabetes mellitus", Cochrane Database Syst Rev, 20(3), pp.CD002966~ (2005)
- gui;ph;ioMiller., "St Onge. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes", Ann Pharmacother, 40(7-8), pp.1336~1343 (2006)
- Melikian C., "Adherence to oral antidiabetic therapy in a managed care organization : a comparison of monotherapy, combination therapy, and fixed-dose combination therapy", Clin Ther, 24(3), pp.460~467 (2002)
- Cramer JA., "Medication compliance and persistence : terminology and definitions", Value Health, 11(1), pp.44~47 (2008)
- Vermeire E., "Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus", Cochrane Database Syst Rev, 18(2), pp.CD003638~ (2005)
- Selak V., "Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care", BMJ, 348, pp.g3318~ (2014)
- Bramlage P., "Clinical impact of patient adherence to a fixed-dose combination of olmesartan, amlodipine and hydrochlorothiazide", Clin Drug Investig, 34(6), pp.403~411 (2014)
- Gu N., "Comparison of the bioavailability and tolerability of fixed-dose combination glimepiride", metformin 2, ClinTher, pp.2010, 32(7)[DOI]
- Migoya EM., "Bioequivalence of sitagliptin", metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects, 2010, pp.30(12), 855~866
- He YL., "Bioequivalence of vildagliptin", metformin fixed-dose combination tablets and a free combination of vildagliptin and metformin in healthy subjects, 2008, pp.46(5), 259~267
- Lau DT., "Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes", Diabetes Care, 27(9), pp.2149~2153 (2004)
- American Diabetes Association., "Standards of medical care in diabetes-2014", Diabetes Care, 37(suppl 1), pp.14~80 (2014)